Biohaven Stock Downgraded Following FDA Regulatory Setback for Troriluzole

Key Facts

1Biohaven stock saw a significant rally on Monday following a positive recommendation from a market pundit.

2The analyst expects the stock price to more than double from its current levels.

Biohaven Ltd. (BHVN) has been downgraded from 'Strong Buy' to 'Hold' following a Complete Response Letter (CRL) from the FDA regarding its drug troriluzole for Spinocerebellar Ataxia. This regulatory setback has prompted the company to pivot its strategic focus toward other late-stage pipeline programs, including taldefgrobep alfa for obesity treatment. Investors are now looking toward the second half of 2026 for phase 2 proof-of-concept data on the obesity candidate. Additionally, the company is prioritizing its Kv7 activator, Opakalim, and its protein degrader platforms, BHV-1400 and BHV-1300. While previous analyst sentiment was highly bullish, the current shift reflects a more cautious outlook as the company navigates regulatory hurdles and extended data timelines.

6 months ago

Version History

Version 16 months ago

What changed: Headline and body updated to reflect the rating downgrade from 'Strong Buy' to 'Hold' following the FDA's rejection of troriluzole and the company's strategic pivot to its obesity pipeline.